Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Malignt Pleural Effusion - Overview
Malignt Pleural Effusion - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Malignt Pleural Effusion - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Malignt Pleural Effusion - Companies Involved in Therapeutics Development
Amgen Inc
Biogen Inc
BioSyngen Pte Ltd
Clover Biopharmaceuticals
Genelux Corp
Gongwin Biopharm Holdings Co Ltd
Hubei Soundny Bio-Tech Co Ltd
Lipac Oncology LLC
Malignt Pleural Effusion - Drug Profiles
BG-00001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BSG-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methotrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olvimulogene nivacirepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paclitaxel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTS-500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talimogene laherparepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Malignt Pleural Effusion - Dormant Projects
Malignt Pleural Effusion - Product Development Milestones
Featured News & Press Releases
Jan 10, 2020: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in Chi for Malignt Pleural Effusions (MPE)
Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignt Pleural Effusions (MPE)
Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in Chi for Malignt Ascites
May 12, 2015: Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015
Jun 15, 2013: Genelux Presents Abstracts at the 7th Intertiol Meeting on Replicating Oncolytic Virus Therapeutics in Quebec
May 30, 2013: Genelux To Present Abstracts For Clinical Trials Of Oncolytic Viral Therapy GL-ONC1 At 2013 ASCO Annual Meeting
Feb 06, 2013: Genelux Announces Treatment Of First Patient In Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Malignant Pleural Effusion, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Malignant Pleural Effusion, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Malignant Pleural Effusion - Pipeline by Amgen Inc, H2 2020
Malignant Pleural Effusion - Pipeline by Biogen Inc, H2 2020
Malignant Pleural Effusion - Pipeline by BioSyngen Pte Ltd, H2 2020
Malignant Pleural Effusion - Pipeline by Clover Biopharmaceuticals, H2 2020
Malignant Pleural Effusion - Pipeline by Genelux Corp, H2 2020
Malignant Pleural Effusion - Pipeline by Gongwin Biopharm Holdings Co Ltd, H2 2020
Malignant Pleural Effusion - Pipeline by Hubei Soundny Bio-Tech Co Ltd, H2 2020
Malignant Pleural Effusion - Pipeline by Lipac Oncology LLC, H2 2020
Malignant Pleural Effusion - Dormant Projects, H2 2020